Introduction {#sec1-1}
============

Digitalis preparations are widely prescribed for children and adults with heart diseases worldwide ([@ref1], [@ref2]), although these preparations are potent medications and excessive doses may cause cardiac, gastrointestinal, neurologic, and metabolic effects. Today, digitalis toxicity continues to be a problem for pediatric patients undergoing therapy with cardiac glycosides for heart failure or arrhythmias, as well as in accidental ingestions. There are several reports presenting acute or chronic digitalis intoxications in children in the literature ([@ref3], [@ref4]). Deaths from digitalis toxicity are usually because of the lethal rhythm disturbances. Additionally, these cardiac arrhythmias significantly affect heart function, posing a risk to the patient's life if not suitably treated. Thus, different antiarrhythmic medications and digoxin-specific antibody Fab fragments are commonly used in the treatment. Also, digoxin-specific antibody Fab fragments are effective in ameliorating the signs of digitalis poisoning in children. Not only can Fab fragments rapidly eradicate potentially life-threatening arrhythmias and conduction defects, they are also effective in treating hyperkalemia and other noncardiac manifestations of digitalis toxicity ([@ref5]). However, alternative and effective medications should be evaluated.

Several species of the genus *Crataegus* have been reported to possess a wide range of pharmacological actions ([@ref6]-[@ref12]). Preparations of *Crataegus* are used in minor forms of coronary heart disease, heart failure, and cardiac arrhythmia. Crataegus has antioxidant ([@ref13], [@ref14]), positive inotropic ([@ref15]), anti-inflammatory ([@ref16], [@ref17]), anti-cardiac remodeling ([@ref18]), antiplatelet aggregation ([@ref19], [@ref20]), vasodilating ([@ref21]-[@ref23]), endothelial protective ([@ref24]), smooth muscle cell migration and proliferation-reducing ([@ref25]), ischemia/reperfusion injury protective ([@ref26], [@ref27]), lipid-lowering ([@ref28], [@ref29]), arterial blood pressure-decreasing ([@ref30], [@ref31]), and antiarrhythmic effects ([@ref8]-[@ref10]). Although some species of Crataegus have been shown to prevent cardiac arrhythmias induced by aconitine, calcium chloride, adrenaline ([@ref32]), and the ischemic process ([@ref10]), its antiarrhythmic effect on digoxin-induced arrhythmias has not yet been demonstrated. The aim of this study is to evaluate the antiarrhythmic effect of Crataegus oxyacantha extract on digoxin-induced arrhythmias in Wistar rats.

Methods {#sec1-2}
=======

Study design {#sec2-1}
------------

A total of 15 rats (7 as controls and 8 as the experimental group) were included in the study. Wistar rats were taken from Kombassan Experimental Medicine Research and Application Center.

Extract preparation {#sec2-2}
-------------------

The dry fruits of 100 mg Crataegus oxyacantha were extracted (1:10) with 100% ethanol at 25°C for 3 hours, the particle size was 2-3 mm, the production method was percolation ([@ref32]), and the flow speed of the extract was 0.5 mL/min ([@ref32]). The suspension was centrifuged at 9000 rpm for 20 min. The supernatant was filtered through 0.20-μm pores. After the filtration, the extract was concentrated under reduced pressure to remove the ethanol. The dried substance was dissolved in 0.9% NaCl with pH 7.4 to form an extract of 5 mg/mL.

Surgical procedure {#sec2-3}
------------------

A total of 15 rats (7 as controls and 8 as the experimental group) were included in the study. Male Wistar rats (280-300 g) were anesthetized with 29 mg/kg xylazine 2% (Rompun, Bayer, MISSISSAUGA, Canada) and 39 mg/kg ketamine (Ketalar, 50 mg/mL, (Ketalar, 50 mg/mL, Pfizer, İstanbul, Turkey). The systemic arterial blood pressure was recorded from a catheter inserted into the left carotid artery. The right and left jugular veins were cannulated for administration of anesthetic or extract solutions.

Digoxin-induced arrhythmias {#sec2-4}
---------------------------

Before the beginning of the study, 6 rats were used to determine the arrhythmic dose of digoxin infusion. The intravenous form of digoxin (0.50 mg/2 mL, Novartis) was used. Digoxin was infused from the left jugular vein of the rats, and the starting dose was 5 μg/kg/min during 60 min. If no arrhythmic effect (QRS prolongation, atrial and ventricular arrhythmias) was observed, the dose was increased gradually up to 40 μg/kg/min ([@ref33]-[@ref35]). Finally, the arrhythmic effect (QT prolongation) was stored at an infusion dose of 40 μg/kg/min after about 10 min. Multiple arrhythmias, such as supraventricular arrhythmias, ventricular tachycardia, and multiple premature ventricular extrasystole, were observed in different rats during the first step of the study. To standardize the arrhythmias in all rats, QRS prolongation, the duration of premature atrial contractions, ventricular extrasystole, ventricular tachycardia, and ventricular fibrillation were measured in all rats.

Extract administration {#sec2-5}
----------------------

The rats were randomly divided into 2 groups: 7 rats for controls and 8 rats for extract infusion (experimental group). After stabilization of the rats (30 min), digoxin infusion was started into all rats at a dose of 40 μg/kg/min into the left jugular vein. Also, simultaneously, 0.9% NaCl infusion was started at a dose of 1 ml/kg/min in the control group, while Crataegus oxyacantha extract was infused into the right jugular vein at a dose of 4 mg/kg/min in the experimental group ([@ref9], [@ref10]). The drug infusions (digoxin, 0.9% NaCl, Crataegus oxyacantha extract) were continued for 60 min.

Data measurements and arrhythmias analysis {#sec2-6}
------------------------------------------

The standard extremity electrocardiography leads were placed into four extremities near the thoracic and abdominal regions, where the electrocardiography waves were recorded best. Electrocardiograms were monitored (MP36, BIOPAC Systems, Inc., California, USA) continuously during the experiment. The heart rate was calculated from the electrocardiographic records. Ventricular arrhythmias and QT prolongation were analyzed according to the guidelines of the Lambeth Conventions for the determination of experimental arrhythmias ([@ref36]). Also, arterial blood pressure was continuously recorded by a transducer (TSD104A, BIOPAC Systems, Inc., California, USA) from a catheter that was inserted into the left carotid artery. All data were analyzed by a computer program (AcqKnowledge BIOPAC Systems, Inc., California, USA).

Statistical analysis {#sec2-7}
--------------------

All statistical analyses were performed by SPSS for Windows, version 16.0 (SPSS Inc, Chicago, Illinois, USA). All results were given as mean±SD. Normal assumptions were assessed before using parametric tests. Wilcoxon test was used to compare the QT prolongation time and time to death in rats. Also, Kruskal-Wallis and ANOVA tests were used for other parametric measurements and intergroups, respectively. A value of *p*\<0.05 was used to indicate statistical significance.

Results {#sec1-3}
=======

After the stabilization period (heart rate and arterial blood pressures were stabilized in 30 min.) was completed, digoxin infusion was started in the two groups. Digoxin infusion in anesthetized rats (all control and experimental groups) resulted in QRS prolongation, bradycardia, and asystole. [Table 1](#T1){ref-type="table"} summarizes the effects of Crataegus oxyacantha extract on electrocardiography. Bradycardia started at 21.03±1.67 min. and 27.12±2.61 min. in the control and experimental groups, respectively. The experimental group lived longer (62.13±2.20 min) than the controls (49.86±2.34 min), and the statistical difference was significant (p=0.002) ([Fig. 1](#F1){ref-type="fig"}). Also, only one rat was alive in the experiment group after digoxin infusion. On the other hand, the time to beginning of QRS prolongation did not differ between the two groups (p=0.812) ([Fig. 2](#F2){ref-type="fig"}). Although the heart rate was similar between the two groups during the stabilization period, it decreased gradually in all rats by digoxin infusion. However, bradycardia was significant in the control group (288.01±10.54 beat/min and p=0.01). Also, heart rate decreased in the experimental group during the digoxin and extract infusion periods (306.31±12.79 beat/min and p=0.01). The maximum QRS duration was observed in the control group during the digoxin and 0.9% NaCl infusion period (53.29±3.99 ms vs. 43.25±1.98 and p=0.001). Additionally, QRS duration was longer during the digoxin and extract infusion period than in the stabilization period in the experimental group (43.25±1.98 ms and p=0.001) ([Fig. 3](#F3){ref-type="fig"}).

###### 

Comparison of the data measured from control and experimental groups

                                                   Control group (n: 7)       Experimental group (n: 8)                      *P*                                                                         
  ------------------------------------------------ -------------------------- ---------------------------------------------- -------------------------- ------------------------------------------------ -----------
  Survival, minutes                                49.86±2.34                 62.13+2.20                                     0.002                                                                       
  Time to beginning of QRS prolongation, minutes   28.01±1.99                 29.94+2.47                                     0.812                                                                       
                                                   **Stabilization period**   **Digoxin with 0.9% NaCl infusion**            **Stabilization period**   **Digoxin with extract infusion**                **ANOVA**
  Heart rate, beats/minute                         366.41±10.28               288.01+10.54[\*](#t1f1){ref-type="table-fn"}   345.51+9.41                306.31+12.79[\*\*](#t1f2){ref-type="table-fn"}   0.01
  Maximum QRS duration, milliseconds               32.71±1.34                 53.29+3.99[\*](#t1f1){ref-type="table-fn"}     31.38+0.90                 43.25+1.98[\*\*](#t1f2){ref-type="table-fn"}     0.001
  Blood pressure, mm Hg                            125.12+11.54               45.34+12.45[\*](#t1f1){ref-type="table-fn"}    123.09+14.05               23.67+10.89[\*\*](#t1f2){ref-type="table-fn"}    \<0.001

Digoxin with 0.9% NaCl infusion vs. all groups;

Digoxin with extract infusion vs. all groups
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![The durations of QRS prolongations in the study population during the experimental period](AJC-15-970-g003){#F3}

In the experimental group, the durations of premature atrial contractions (6.23±2.53 min), ventricular extrasystole (29.25±1.98 min), ventricular tachycardia (39.19±8.02 min), and ventricular fibrillation (11.94±4.46 min) were significantly shorter than in the control group ([Table 2](#T2){ref-type="table"}).

###### 

Effects of ethanol extract of Crataegus oxyacantha on digoxin-induced arrhythmias in study groups

  Arrhythmia type                 Duration of arrhythmia, minutes                
  ------------------------------- --------------------------------- ------------ ---------
  Premature atrial contractions   13.45±5.21\*                      6.23±2.53    \<0.001
  Ventricular extrasystole        48.56±7.19\*                      29.25±1.98   \<0.001
  Ventricular tachycardia         41.25±7.03\*                      39.19±8.02   \<0.001
  Ventricular fibrillation        23.12±6.71\*                      11.94±4.46   \<0.001

Arterial blood pressures decreased gradually in all rats. However, blood pressure dipping was significant in the experimental group (23.67±10.89 mm Hg and p\<0.001). Additionally, arterial blood pressure decreased in the control group during the digoxin and extract infusion period (45.34±12.45 mm Hg and p\<0.001) ([Fig. 4](#F4){ref-type="fig"}).

![Arterial blood pressure variations in the study population during the experimental period](AJC-15-970-g004){#F4}

Discussion {#sec1-4}
==========

In the present study, the alcoholic extract of Crataegus oxyacantha produced a protective effect against digoxin-induced arrhythmias. In our study, we used QRS prolongation and durations of premature atrial contractions, ventricular extrasystole, ventricular tachycardia, and ventricular fibrillation as predictive markers of arrhythmias because of the observation of multiple arrhythmia types in different rats. Also, our study demonstrated that these atrial and ventricular arrhythmias were decreased in the experimental group, in which the ethanol extract of Crataegus oxyacantha was infused with digoxin. The studies that evaluated digoxin-induced cardiac toxicity in animal models revealed that multiple ventricular and supraventricular arrhythmias were observed during the study periods ([@ref33]-[@ref35]). However, QRS prolongation starts earlier than these cardiac arrhythmias. Animal studies showed that digitalis-induced Na+ accumulation results in an increase in Ca^2^+, via the Na+/Ca^2^+ exchanger, leading to enhanced sarcoplasmic reticulum Ca^2^+ load, responsible for the positive inotropic and toxic arrhythmogenic effects of glycosides ([@ref37]). Also, a recent study of Gonano et al. ([@ref38]) demonstrated that active calcium-calmodulin kinase II mediates ouabain-induced arrhythmic and toxic effects by phosphorylation of the ryanodine receptor, resulting in Ca^2^+ leakage from the sarcoplasmic reticulum. The exact mechanism underlying the antiarrhythmic effect of Hawthorn species remains unclear. However, in a study, it was shown that Crataegus extract prolonged the action potential duration and delayed the recovery of V~max~ ([@ref39]). On the other hand, concerns have been raised regarding the blocking of repolarizing potassium currents in ventricular myocytes, which is similar to the action of class III antiarrhythmic drugs ([@ref40]). The extract of different Hawthorn species may affect these pathways to produce their antiarrhythmic effects. Also, it was found that especially saponin and flavonoid fractions from different Hawthorn species produce a decrease in arterial blood pressure and an antiarrhythmic effect ([@ref32], [@ref37]).

Hawthorn (Crataegus species) plant extracts and medications have been recognized internationally as source of medicine worldwide. The source material contains a range of pharmacologically active substances, including flavonoids, triterpenic acids, and phenol carboxylic acids ([@ref32], [@ref37]). Despite a number of preclinical and clinical studies, the mechanisms of the protective effects of Hawthorn extracts remain poorly understood ([@ref6]-[@ref12]). Moreover, there are limited findings on its action in protecting arrhythmias in animal studies ([@ref8]-[@ref10]).

The preliminary study of Thompson et al. ([@ref9]) revealed that extract of the bark and leaves of Crataegus monogyna possessed prophylactic antiarrhythmic activity in rabbits. Also, they used aconitine to induce the arrhythmias in their study. Similarly, Garjani et al. showed that the extract of Crataegus meyeri has a hypotensive and potential antiarrhythmic effect on ischemic myocardium in rats ([@ref10]). They included hydroalcohol, chloroform, and ethylacetate extracts in the study. Also, the study revealed that each form of extract had different reducing effects on ventricular arrhythmias ([@ref10]). On the other hand, a recent study of Salehi et al. ([@ref8]) revealed that Crataegus monogyna extract decreased the contraction frequency of neonatal murine cardiomyocytes via muscarinic receptor activation. So, this finding suggests the atropine-sensitive activity of Hawthorn extracts. Additionally, Swaminattan et al. ([@ref12]) reported that Crataegus oxyacantha extract reduced oxidative stress in reperfused myocardium, and it played a significant role in the inhibition of apoptotic pathways, leading to cardioprotection.

Koçyıldız et al. ([@ref30]) showed that the hyperoside fraction of Crataegus prevented L-NAME-induced hypertension in rats and had beneficial effects on the cardiovascular system. Crataegus, administered at escalating doses, produced a dose- and time-dependent decrease in heart rate and mean arterial pressure. Also, higher doses produced the most significant reduction in both heart rate and mean arterial pressures. Shatoor et al. ([@ref31]) suggested that the underlying mech anism that leads to hypotension appeared to be related to direct stimulation of the muscarinic receptor M2 and possible blockade of beta-receptors. In our study, in the experimental group, maximal arterial blood dipping was observed. This may be due to the total effect of digoxin toxicity and the effect of Crataegus oxyacantha extract.

Study limitations {#sec1-5}
=================

We did not use other extracts of Crataegus oxyacantha, such as hydroalcohol or chloroform, for analysis in the study. Also, a standard infusion dose (40 mcg/kg/min) was used for digoxin; it was not increased. Additionally, a small number of selected groups of rats were used in the study.

Conclusion {#sec1-6}
==========

Finally, as demonstrated in the present study, Crataegus oxyacantha alcoholic extract produced antiarrhythmic effects against arrhythmia induced by digoxin in Wistar rats. However, in the clinical use of this extract, the hypotensive effect should be considered. Alcoholic extract of Crataegus oxyacantha may be an alternative treatment medication for arrhythmias induced by digoxin toxicity in humans. So, further studies are needed for this suggestion.
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